Desmoteplase for Acute Ischemic Stroke within 3 to 9 Hours after Symptom Onset: Evidence from Randomized Controlled Trials.
Recent studies have shown inconsistent results regarding the value of desmoteplase for treating acute ischemic stroke (AIS) when administered within an extended time window. We performed a meta-analysis to explore the value of desmoteplase in AIS treatment. The MEDLINE, EMBASE, and Cochrane Library databases were searched for randomized controlled trials (RCTs) that had evaluated desmoteplase versus placebo for AIS. The primary outcomes were intracranial hemorrhage (ICH) within 72 hours and favorable outcome at Day 90. We pooled 819 patients from 5 RCTs. Desmoteplase treatment showed a neutral effect on favorable outcome (P = 0.42) but a favorable safety profile in terms of ICH (P = 0.64) compared with the placebo group. In the subgroup analysis, 90 μg/kg desmoteplase, a late time to treatment (6-9 hours), and serious stroke symptoms at baseline (NIHSS > 12) subgroups showed high risks of ICH (P ≤ 0.02). A high dose of desmoteplase (125 μg/kg) showed a tendency to improve recanalization (P = 0.05), but was also associated with an increased risk of death (P = 0.04). In conclusion, desmoteplase administered over an extended time window had no significant effect on functional recovery but exhibited a favorable safety profile in patients with AIS.
Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Ligen
L
Shi
Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Feng
F
Liang
Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Yunping
Y
Li
Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Anwen
A
Shao
Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Keren
K
Zhou
Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Jun
J
Yu
Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.|Brain Research Institute, Zhejiang University, Hangzhou, Zhejiang, China.|Collaborative Innovation Center for Brain Science, Zhejiang University, Hangzhou, Zhejiang, China.
Jianmin
J
Zhang
Blood. 2012 May 17;119(20):4752-61
22262761
Lancet. 2004 Mar 6;363(9411):768-74
15016487
Stroke. 2006 May;37(5):1227-31
16574922
Stroke. 2009 Feb;40(2):469-75
19109547
Stroke. 2005 Jan;36(1):66-73
15569863
Stroke. 2015 Oct;46(10):3020-35
26123479
Ann Neurol. 1997 May;41(5):581-9
9153519
N Engl J Med. 1995 Dec 14;333(24):1581-7
7477192
J Clin Epidemiol. 2009 Oct;62(10):1006-12
19631508
Sci Rep. 2015 Nov 02;5:16026
26522691
Stroke. 2005 Jun;36(6):1153-9
15914768
Lancet Neurol. 2006 Aug;5(8):661-7
16857571
Sci Rep. 2016 Feb 10;6:20932
26860196
Lancet Neurol. 2009 Feb;8(2):141-50
19097942
Br J Pharmacol. 2012 Jan;165(1):75-89
21627637
Stroke. 2008 Sep;39(9):2491-6
18635861
Stroke. 2005 Jun;36(6):1241-6
15879331
Lancet Neurol. 2015 Jun;14(6):575-84
25937443
Stroke. 2004 Feb;35(2):486-90
14707233
Sci Rep. 2016 Jun 14;6:27880
27296511
CNS Drugs. 2016 Feb;30(2):101-8
26798040
Ann Neurol. 2006 Nov;60(5):508-17
17066483
Lancet Neurol. 2015 Jun;14(6):560-1
25937441
Stroke. 2016 Mar;47(3):901-3
26846865
Stroke. 2015 Sep;46(9):2549-54
26251244
J Cereb Blood Flow Metab. 2010 Jun;30(6):1214-25
20087363
Ann Neurol. 1999 Oct;46(4):568-78
10514093
Stroke. 2007 Mar;38(3):967-73
17272772
Lancet Neurol. 2008 Apr;7(4):299-309
18296121
JAMA Neurol. 2015 Aug;72(8):928-34
26030910
Sci Rep. 2015 Jul 24;5:11743
26206308